BioMarin (BMRN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The fourth beaten-down stock with an apparent price dislocation that I bought during Wall Street's historic volatility is ...

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report) and Amgen (AMGN – Research ...

RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...

The American trade structure is witnessing a transformative shift, thanks to the Trump administration’s sweeping new tariff ...

The Argentina inborn errors of protein metabolism (IEPM) market was valued at US$ 268.2 million in 2023 and is expected to achieve a market valuation of US$ 664.0 million by 2032. This impressive ...

Patients with hereditary angioedema who switched from other drugs to donidalorsen for long-term prophylaxis experienced fewer attacks and improved disease control, according to a poster presented here ...